Arbutus Biopharma (ABUS) Times Interest Earned (2013 - 2026)
Arbutus Biopharma (ABUS) posted Times Interest Earned of $7343.8 for Q1 2026, up 2598.84% sequentially from -$293.89 in Q4 2025, and up 900.14% YoY from $734.28 in Q1 2025.
Arbutus Biopharma (ABUS) Times Interest Earned (2013 - 2026) Analysis & Trends
Arbutus Biopharma has reported Times Interest Earned for 14 years, with the latest figure at $7343.8 in Q1 2026.
- Quarterly Times Interest Earned rose 900.14% year-over-year to $7343.8 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6802.0 (up 6263.85% YoY) and the FY2025 annual result came in at -$0.21, up 51.64% from the prior year.
- Times Interest Earned advanced to $7343.8 in Q1 2026 per ABUS's latest filing, from -$293.89 in the prior quarter.
- Over five years, Times Interest Earned peaked at $7343.8 in Q1 2026 and troughed at -$917.82 in Q1 2025.
- A 5-year average of $221.26 and a median of -$107.51 in 2023 frame the typical range for Times Interest Earned.
- The sharpest annual moves came in 2023 and 2026: Times Interest Earned sank 1028.81% in 2023, then surged 900.14% in 2026.
- Over 5 years, Times Interest Earned stood at -$73.02 in 2022, then tumbled by 55.27% to -$113.37 in 2023, then soared by 75.86% to -$27.37 in 2024, then sank by 973.63% to -$293.89 in 2025, then surged by 2598.84% to $7343.8 in 2026.
- According to Business Quant data, Times Interest Earned over the past three periods registered $7343.8, -$293.89, and -$376.48 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Arbutus Biopharma | 922.95 Mn | 830.33 Mn | - | -99.40 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -99.40 |
| Mar 31, 2026 | 7,343.83 |
| Dec 31, 2025 | -293.89 |
| Sep 30, 2025 | -376.48 |
| Jun 30, 2025 | 53.14 |
| Mar 31, 2025 | -917.82 |
| Dec 31, 2024 | -27.37 |
| Sep 30, 2024 | -739.31 |
| Jun 30, 2024 | -222.51 |
| Mar 31, 2024 | -115.26 |
| Dec 31, 2023 | -113.37 |
| Sep 30, 2023 | -468.65 |
| Jun 30, 2023 | -107.51 |
| Mar 31, 2023 | -87.94 |
| Dec 31, 2022 | -73.02 |
| Sep 30, 2022 | -41.52 |
| Jun 30, 2022 | -29.27 |
| Mar 31, 2022 | -21.69 |
| Dec 31, 2021 | 12.63 |
| Sep 30, 2021 | -24.16 |